Selected Among the National Top 100
From November 22 to 24, 2022, the three-day "Innovation China" Innovation and Entrepreneurship Investment Conference expert final review was held in Shenzhen. Themed "Smart Innovation China — Illuminate Dreams," the conference evaluated 8,663 projects from six major industry sectors collected from across the country. After two rounds of online screening, 200 outstanding projects were shortlisted for the final selection to determine the national top 100. Medgen Life Science was successfully selected among the national top 100.
During the event, Medgen presented a professional market analysis of the domestic orthopedic market and introduced the company's technically advanced resorbable artificial bone. Through continuous breakthroughs and innovation in regenerative repair materials, Medgen is breaking through foreign technological barriers and price monopolies, achieving domestic substitution, and injecting new vitality into the domestic high-end orthopedic implant market.
Competition Background
On May 10, 2022, the "Innovation China" Innovation and Entrepreneurship Investment Conference (2022) was officially launched, soliciting projects from around the world to identify rising stars in emerging technology fields. The conference closely aligned with strategic emerging industry development, covering six major sectors: next-generation information technology, biomedicine, high-end equipment manufacturing, new materials, green and low-carbon technologies, and the digital economy.
Concurrently, China's National Development and Reform Commission released the "14th Five-Year Plan for Bioeconomic Development," specifically calling for strengthened support for biotech companies pursuing domestic capital market listings. The plan outlined 28 measures across eight areas — including consolidating the bioeconomy innovation foundation, expanding bioeconomy pillar industries, and advancing biological resource conservation and utilization — to promote China's bioeconomic development. Medgen will actively respond to policy initiatives and strive to be a pioneer in China's biomedical industry.